Accelerate to discover

Back to filter

Related topics

Imaging Performance of a multimodal module to enhance preclinical irradiator capabilities

Precision X-Ray

Sep 15, 2020

Upgrading an existing irradiator with such a multi-modal imaging device is a reasonable investment in laboratories...

Are you still using traditional methodologies for your Oncology cell metabolism studies?

Sartorius

Sep 10, 2020

In this infographic, learn about the challenges experienced by scientists in analysing cellular metabolism and how...

Using DNA repair and machine learning to improve cancer risk prediction

Luminex

Sep 7, 2020

Across the world, breast cancer continues to be the leading type of cancer in women, accounting for 25% of all cases....

Quantitative evaluation of pulmonary function with hyperpolarized xenon gas MR

Bruker Biospin

Aug 20, 2020

Hyperpolarized 129Xe MR has been proven to be a powerful tool to evaluate the pulmonary function and has been widely...

Sep 19, 2020

Applications of Hyperpolarized 129Xe MRI for functional imaging of the lungs

Bruker Biospin

Aug 11, 2020

2015 marked the first ever translation of hyperpolarized gas MRI to diagnostic clinical practice. Research at the...

Detection of Rare Cells and Circulating Tumor Cells using NovoCyte flow cytometer

Acea Biosciences

Aug 11, 2020

Circulating tumor cells (CTC) are rare cells shed from a solid tumor or metastases that circulate through the...

Introducing Amnis AI Image Analysis software

Luminex

Aug 4, 2020

Amnis AI Image Analysis Software combines the power of high dimensional data reduction with artificial intelligence,...

Sep 19, 2020

Micro-CT: Fancy gadget or indispensable technology towards quantification of lung diseases?

Bruker Biospin

Jul 29, 2020

Technology allowing evaluation of live animals repeatedly is indispensable to gain better insight into the dynamics of...

Show all topics (10)

Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.

Jun 4, 2018

Both HIV and Tuberculosis are considered to be one of the most dangerous infectious diseases in the world. Quite often these two pathogens work in synchrony, making the risk of patient´s death twice as high. To solve this problem researchers from the Engelhardt Institute of Molecular biology in Russia cooperated with the National Institute of Health in the USA. They created compounds with dual activity against both pathogens by creating a heterodimer based on nucleosides. These heterodimers have two active components with two different rates of release based on the speed of their hydrolysis. They tested five of such compounds on HIV and Tuberculosis strain MS-114, which is drug-resistance. Drug-resistance of tuberculosis is one of the main problems in the treatment nowadays.

The compounds were judged based on the ability to inhibit these pathogens. Additionally, a testing on the host tissue was done using NovoCyte. The researchers tested the viability of mammalian lymphoid tissue after treatment. The results show that the heterodimers are non-toxic and non-static towards the cells while maintaining the potency against the pathogens. So far the compound was tested in vivo and ex vitro and seem to be a very promising solution. These results bring interesting insight and novel approach toward treatment of both HIV and Tuberculosis.

Want to know more?

Scientific paper
Application

Related technologies: Conventional flow cytometry

Brand profile

Acea Biosciences

ACEA manufactures xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

The best in class personalized flow cytometer

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey